Lexeo Therapeutics, INC 8-K filings

NASDAQ

16 Apr 2024

LXEO

8-K: Lexeo Therapeutics Receives FDA Fast Track Designation for Gene Therapy LX2006

Lexeo Therapeutics has been granted Fast Track designation by the FDA for its gene therapy candidate, LX2006, aimed at treating Friedreich's ataxia cardiomyopathy.

NASDAQ

11 Mar 2024

LXEO

Lexeo Therapeutics, INC

8-K: Lexeo Therapeutics Secures $95 Million in Private Placement, Extends Cash Runway into 2027

Lexeo Therapeutics has announced a $95 million private placement to fund operations into 2027, alongside positive clinical trial updates and 2023 financial results.

NASDAQ

5 Feb 2024

LXEO

Lexeo Therapeutics, INC

8-K: Lexeo Therapeutics Bolsters Leadership Team with Key Executive Appointments

Lexeo Therapeutics has announced the appointment of several new executives to lead the company's pipeline into late-stage clinical development.